The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Therapeutic Cancer Vaccines Market Research Report 2025
Synopsis
Genetic vaccines are emerging as promising methodologies to elicit immune responses against a wide variety of antigens.
The global Therapeutic Cancer Vaccines market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Therapeutic Cancer Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Therapeutic Cancer Vaccines.
Report Scope
The Therapeutic Cancer Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Therapeutic Cancer Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Therapeutic Cancer Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Antigenics
Asterias Biotherapeutics
Avax Technologies
Bayer
GlaxoSmithKline
Mayo Clinic
Merck
Moderna
Northwest Biotherapeutics
VAXIMM
Segment by Type
Whole Cell Vaccine
Antigen Vaccine
Non-specific and Cytokine Strategies
Others
Segment by Application
Bladder Cancer
Brain Tumors
Breast Cancer
Lung Cancer
Prostate Cancer
Cervical Cancer
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Therapeutic Cancer Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Therapeutic Cancer Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Genetic vaccines are emerging as promising methodologies to elicit immune responses against a wide variety of antigens.
The global Therapeutic Cancer Vaccines market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Therapeutic Cancer Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Therapeutic Cancer Vaccines.
Report Scope
The Therapeutic Cancer Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Therapeutic Cancer Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Therapeutic Cancer Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Antigenics
Asterias Biotherapeutics
Avax Technologies
Bayer
GlaxoSmithKline
Mayo Clinic
Merck
Moderna
Northwest Biotherapeutics
VAXIMM
Segment by Type
Whole Cell Vaccine
Antigen Vaccine
Non-specific and Cytokine Strategies
Others
Segment by Application
Bladder Cancer
Brain Tumors
Breast Cancer
Lung Cancer
Prostate Cancer
Cervical Cancer
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Therapeutic Cancer Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Therapeutic Cancer Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Therapeutic Cancer Vaccines Market Overview
1.1 Product Overview and Scope of Therapeutic Cancer Vaccines
1.2 Therapeutic Cancer Vaccines Segment by Type
1.2.1 Global Therapeutic Cancer Vaccines Market Value Comparison by Type (2024-2030)
1.2.2 Whole Cell Vaccine
1.2.3 Antigen Vaccine
1.2.4 Non-specific and Cytokine Strategies
1.2.5 Others
1.3 Therapeutic Cancer Vaccines Segment by Application
1.3.1 Global Therapeutic Cancer Vaccines Market Value by Application: (2024-2030)
1.3.2 Bladder Cancer
1.3.3 Brain Tumors
1.3.4 Breast Cancer
1.3.5 Lung Cancer
1.3.6 Prostate Cancer
1.3.7 Cervical Cancer
1.3.8 Others
1.4 Global Therapeutic Cancer Vaccines Market Size Estimates and Forecasts
1.4.1 Global Therapeutic Cancer Vaccines Revenue 2019-2030
1.4.2 Global Therapeutic Cancer Vaccines Sales 2019-2030
1.4.3 Global Therapeutic Cancer Vaccines Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Therapeutic Cancer Vaccines Market Competition by Manufacturers
2.1 Global Therapeutic Cancer Vaccines Sales Market Share by Manufacturers (2019-2024)
2.2 Global Therapeutic Cancer Vaccines Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Therapeutic Cancer Vaccines Average Price by Manufacturers (2019-2024)
2.4 Global Therapeutic Cancer Vaccines Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Therapeutic Cancer Vaccines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Therapeutic Cancer Vaccines, Product Type & Application
2.7 Therapeutic Cancer Vaccines Market Competitive Situation and Trends
2.7.1 Therapeutic Cancer Vaccines Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Therapeutic Cancer Vaccines Players Market Share by Revenue
2.7.3 Global Therapeutic Cancer Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Therapeutic Cancer Vaccines Retrospective Market Scenario by Region
3.1 Global Therapeutic Cancer Vaccines Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Therapeutic Cancer Vaccines Global Therapeutic Cancer Vaccines Sales by Region: 2019-2030
3.2.1 Global Therapeutic Cancer Vaccines Sales by Region: 2019-2024
3.2.2 Global Therapeutic Cancer Vaccines Sales by Region: 2025-2030
3.3 Global Therapeutic Cancer Vaccines Global Therapeutic Cancer Vaccines Revenue by Region: 2019-2030
3.3.1 Global Therapeutic Cancer Vaccines Revenue by Region: 2019-2024
3.3.2 Global Therapeutic Cancer Vaccines Revenue by Region: 2025-2030
3.4 North America Therapeutic Cancer Vaccines Market Facts & Figures by Country
3.4.1 North America Therapeutic Cancer Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Therapeutic Cancer Vaccines Sales by Country (2019-2030)
3.4.3 North America Therapeutic Cancer Vaccines Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Therapeutic Cancer Vaccines Market Facts & Figures by Country
3.5.1 Europe Therapeutic Cancer Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Therapeutic Cancer Vaccines Sales by Country (2019-2030)
3.5.3 Europe Therapeutic Cancer Vaccines Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Therapeutic Cancer Vaccines Market Facts & Figures by Country
3.6.1 Asia Pacific Therapeutic Cancer Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Therapeutic Cancer Vaccines Sales by Country (2019-2030)
3.6.3 Asia Pacific Therapeutic Cancer Vaccines Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Therapeutic Cancer Vaccines Market Facts & Figures by Country
3.7.1 Latin America Therapeutic Cancer Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Therapeutic Cancer Vaccines Sales by Country (2019-2030)
3.7.3 Latin America Therapeutic Cancer Vaccines Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Therapeutic Cancer Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa Therapeutic Cancer Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Therapeutic Cancer Vaccines Sales by Country (2019-2030)
3.8.3 Middle East and Africa Therapeutic Cancer Vaccines Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Therapeutic Cancer Vaccines Sales by Type (2019-2030)
4.1.1 Global Therapeutic Cancer Vaccines Sales by Type (2019-2024)
4.1.2 Global Therapeutic Cancer Vaccines Sales by Type (2025-2030)
4.1.3 Global Therapeutic Cancer Vaccines Sales Market Share by Type (2019-2030)
4.2 Global Therapeutic Cancer Vaccines Revenue by Type (2019-2030)
4.2.1 Global Therapeutic Cancer Vaccines Revenue by Type (2019-2024)
4.2.2 Global Therapeutic Cancer Vaccines Revenue by Type (2025-2030)
4.2.3 Global Therapeutic Cancer Vaccines Revenue Market Share by Type (2019-2030)
4.3 Global Therapeutic Cancer Vaccines Price by Type (2019-2030)
5 Segment by Application
5.1 Global Therapeutic Cancer Vaccines Sales by Application (2019-2030)
5.1.1 Global Therapeutic Cancer Vaccines Sales by Application (2019-2024)
5.1.2 Global Therapeutic Cancer Vaccines Sales by Application (2025-2030)
5.1.3 Global Therapeutic Cancer Vaccines Sales Market Share by Application (2019-2030)
5.2 Global Therapeutic Cancer Vaccines Revenue by Application (2019-2030)
5.2.1 Global Therapeutic Cancer Vaccines Revenue by Application (2019-2024)
5.2.2 Global Therapeutic Cancer Vaccines Revenue by Application (2025-2030)
5.2.3 Global Therapeutic Cancer Vaccines Revenue Market Share by Application (2019-2030)
5.3 Global Therapeutic Cancer Vaccines Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Antigenics
6.1.1 Antigenics Corporation Information
6.1.2 Antigenics Description and Business Overview
6.1.3 Antigenics Therapeutic Cancer Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Antigenics Therapeutic Cancer Vaccines Product Portfolio
6.1.5 Antigenics Recent Developments/Updates
6.2 Asterias Biotherapeutics
6.2.1 Asterias Biotherapeutics Corporation Information
6.2.2 Asterias Biotherapeutics Description and Business Overview
6.2.3 Asterias Biotherapeutics Therapeutic Cancer Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Asterias Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio
6.2.5 Asterias Biotherapeutics Recent Developments/Updates
6.3 Avax Technologies
6.3.1 Avax Technologies Corporation Information
6.3.2 Avax Technologies Description and Business Overview
6.3.3 Avax Technologies Therapeutic Cancer Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Avax Technologies Therapeutic Cancer Vaccines Product Portfolio
6.3.5 Avax Technologies Recent Developments/Updates
6.4 Bayer
6.4.1 Bayer Corporation Information
6.4.2 Bayer Description and Business Overview
6.4.3 Bayer Therapeutic Cancer Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bayer Therapeutic Cancer Vaccines Product Portfolio
6.4.5 Bayer Recent Developments/Updates
6.5 GlaxoSmithKline
6.5.1 GlaxoSmithKline Corporation Information
6.5.2 GlaxoSmithKline Description and Business Overview
6.5.3 GlaxoSmithKline Therapeutic Cancer Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.5.4 GlaxoSmithKline Therapeutic Cancer Vaccines Product Portfolio
6.5.5 GlaxoSmithKline Recent Developments/Updates
6.6 Mayo Clinic
6.6.1 Mayo Clinic Corporation Information
6.6.2 Mayo Clinic Description and Business Overview
6.6.3 Mayo Clinic Therapeutic Cancer Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Mayo Clinic Therapeutic Cancer Vaccines Product Portfolio
6.6.5 Mayo Clinic Recent Developments/Updates
6.7 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Therapeutic Cancer Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Therapeutic Cancer Vaccines Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Moderna
6.8.1 Moderna Corporation Information
6.8.2 Moderna Description and Business Overview
6.8.3 Moderna Therapeutic Cancer Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Moderna Therapeutic Cancer Vaccines Product Portfolio
6.8.5 Moderna Recent Developments/Updates
6.9 Northwest Biotherapeutics
6.9.1 Northwest Biotherapeutics Corporation Information
6.9.2 Northwest Biotherapeutics Description and Business Overview
6.9.3 Northwest Biotherapeutics Therapeutic Cancer Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Northwest Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio
6.9.5 Northwest Biotherapeutics Recent Developments/Updates
6.10 VAXIMM
6.10.1 VAXIMM Corporation Information
6.10.2 VAXIMM Description and Business Overview
6.10.3 VAXIMM Therapeutic Cancer Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.10.4 VAXIMM Therapeutic Cancer Vaccines Product Portfolio
6.10.5 VAXIMM Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Therapeutic Cancer Vaccines Industry Chain Analysis
7.2 Therapeutic Cancer Vaccines Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Therapeutic Cancer Vaccines Production Mode & Process
7.4 Therapeutic Cancer Vaccines Sales and Marketing
7.4.1 Therapeutic Cancer Vaccines Sales Channels
7.4.2 Therapeutic Cancer Vaccines Distributors
7.5 Therapeutic Cancer Vaccines Customers
8 Therapeutic Cancer Vaccines Market Dynamics
8.1 Therapeutic Cancer Vaccines Industry Trends
8.2 Therapeutic Cancer Vaccines Market Drivers
8.3 Therapeutic Cancer Vaccines Market Challenges
8.4 Therapeutic Cancer Vaccines Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
